Atharva Biopharma Profile
Key Indicators
- Authorised Capital ₹ 10.70 Cr
as on 16-11-2024
- Paid Up Capital ₹ 10.70 Cr
as on 16-11-2024
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 36.50 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Profit 16.62%
(FY 2023)
- Ebitda 77.34%
(FY 2023)
- Net Worth -1.11%
(FY 2023)
- Total Assets 153.79%
(FY 2023)
About Atharva Biopharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.70 Cr and a paid-up capital of Rs 10.70 Cr.
The company currently has active open charges totaling ₹36.50 Cr.
Mohan Jadhav, Mansing Pachundkar, Sanjaykumar Mache, and One other member serve as directors at the Company.
- CIN/LLPIN
U24304PN2019PTC187991
- Company No.
187991
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Nov 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Atharva Biopharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjaykumar Mache  | Additional Director | 26-Jun-2020 | Current |
| Jalindar Padwal | Director | 25-Nov-2019 | Current |
| Mohan Jadhav | Additional Director | 26-Jun-2020 | Current |
| Mansing Pachundkar | Director | 25-Nov-2019 | Current |
Financial Performance of Atharva Biopharma.
Atharva Biopharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 16.62% increase in profit. The company's net worth dipped by a decrease of 1.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Atharva Biopharma?
In 2023, Atharva Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Atharva Corrugations Private LimitedActive 11 years 9 monthsMansing Pachundkar and Sanjaykumar Mache are mutual person
- Atharva Logistics & Engineering Private LimitedActive 6 years 10 months
Mansing Pachundkar is a mutual person
- Atharva Corporate Management Private LimitedActive 5 years 6 months
Mansing Pachundkar and Sanjaykumar Mache are mutual person
Charges (Loans)
₹36.50 Cr
₹0
Charges Breakdown by Lending Institutions
- Karnataka Bank Ltd. : 36.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Oct 2022 | Karnataka Bank Ltd. | ₹36.50 Cr | Open |
How Many Employees Work at Atharva Biopharma?
Unlock and access historical data on people associated with Atharva Biopharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Atharva Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Atharva Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.